TY - JOUR
T1 - Effect of Intensive Blood Pressure Lowering on Incident Atrial Fibrillation and P-Wave Indices in the ACCORD Blood Pressure Trial
AU - Chen, Lin Y.
AU - Bigger, J. Thomas
AU - Hickey, Kathleen T.
AU - Chen, Haiying
AU - Lopez-Jimenez, Carlos
AU - Banerji, Mary Ann
AU - Evans, Gregory
AU - Fleg, Jerome L.
AU - Papademetriou, Vasilios
AU - Thomas, Abraham
AU - Woo, Vincent
AU - Seaquist, Elizabeth R.
AU - Soliman, Elsayed Z.
N1 - Publisher Copyright:
© 2015 American Journal of Hypertension, Ltd 2015. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - BACKGROUND There are no proven strategies to prevent atrial fibrillation (AF) in patients with type 2 diabetes (T2DM). We compared standard blood pressure (BP) lowering vs. intensive BP lowering in reducing incidence of AF or P-wave indices (PWI - ECG markers of left atrial abnormality that are considered intermediate phenotypes of AF) in patients with T2DM. METHODS We analyzed data from the ACCORD BP trial - a randomized controlled nonblinded trial (2001-2009) which randomized patients with T2DM and systolic BP (SBP) 130-180mm Hg on ≤3 antihypertensive medications aged 40-79 years with cardiovascular disease (CVD) or aged 55-79 years with subclinical CVD or ≥2 CVD risk factors to standard BP lowering (SBP <140mm Hg) vs. intensive BP lowering (SBP <120mm Hg). The primary outcome was a composite of incident AF and PWI. RESULTS Data from 3,087 participants (mean age, 62.2 years; women, 48.2%; non-White, 39.2%) were analyzed. During a mean follow-up of 4.4 years, the primary outcome occurred in 1,063 participants (incidence rate, 84.5 per 1,000 person-years in the standard-therapy group vs. 73.9 per 1,000 person-years in the intensive-therapy group). The adjusted hazard ratios (95% confidence intervals) of intensive-therapy group for the primary outcome and for incident PWI alone were 0.87 (0.77-0.98), P = 0.02 and 0.87 (0.76-0.98), P = 0.02, respectively. The effect of intensive therapy on the incidence of AF alone did not reach statistical significance. CONCLUSIONS In patients with T2DM, intensive BP lowering reduces the incidence of the composite outcome of AF and PWI, suggesting a potential benefit from stringent BP control in patients with T2DM.
AB - BACKGROUND There are no proven strategies to prevent atrial fibrillation (AF) in patients with type 2 diabetes (T2DM). We compared standard blood pressure (BP) lowering vs. intensive BP lowering in reducing incidence of AF or P-wave indices (PWI - ECG markers of left atrial abnormality that are considered intermediate phenotypes of AF) in patients with T2DM. METHODS We analyzed data from the ACCORD BP trial - a randomized controlled nonblinded trial (2001-2009) which randomized patients with T2DM and systolic BP (SBP) 130-180mm Hg on ≤3 antihypertensive medications aged 40-79 years with cardiovascular disease (CVD) or aged 55-79 years with subclinical CVD or ≥2 CVD risk factors to standard BP lowering (SBP <140mm Hg) vs. intensive BP lowering (SBP <120mm Hg). The primary outcome was a composite of incident AF and PWI. RESULTS Data from 3,087 participants (mean age, 62.2 years; women, 48.2%; non-White, 39.2%) were analyzed. During a mean follow-up of 4.4 years, the primary outcome occurred in 1,063 participants (incidence rate, 84.5 per 1,000 person-years in the standard-therapy group vs. 73.9 per 1,000 person-years in the intensive-therapy group). The adjusted hazard ratios (95% confidence intervals) of intensive-therapy group for the primary outcome and for incident PWI alone were 0.87 (0.77-0.98), P = 0.02 and 0.87 (0.76-0.98), P = 0.02, respectively. The effect of intensive therapy on the incidence of AF alone did not reach statistical significance. CONCLUSIONS In patients with T2DM, intensive BP lowering reduces the incidence of the composite outcome of AF and PWI, suggesting a potential benefit from stringent BP control in patients with T2DM.
KW - P-wave indices
KW - atrial fibrillation
KW - blood pressure
KW - diabetes mellitus
KW - hypertension
KW - left atrial abnormality
KW - randomized controlled trial
UR - http://www.scopus.com/inward/record.url?scp=84995477571&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84995477571&partnerID=8YFLogxK
U2 - 10.1093/ajh/hpv172
DO - 10.1093/ajh/hpv172
M3 - Article
C2 - 26476086
AN - SCOPUS:84995477571
SN - 0895-7061
VL - 29
SP - 1276
EP - 1282
JO - American Journal of Hypertension
JF - American Journal of Hypertension
IS - 11
ER -